Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Prognostic and Therapeutic Insights Into MIF, DDT, and CD74 in Melanoma

News

July 26, 2024
PRESS RELEASE: On July 19, 2024, a new research paper was published in Oncotarget, entitled, “Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.” continue reading »

Novel Triple-Drug Combination to Fight Pancreatic Cancer

Oncotarget

July 25, 2024
In this new study, researchers unveiled a promising synergistic strategy for combating pancreatic cancer. continue reading »

Prevalence and Impact of the KIT M541L Variant in Patients With Mastocytosis

News

July 24, 2024
PRESS RELEASE: On July 22, 2024, a new research paper was published in Oncotarget, entitled, “Prevalence and impact of the KIT M541L variant in patients with mastocytosis.” continue reading »

Oncotarget Welcomes New Editorial Board Members

News

July 22, 2024
Oncotarget is also offering a 50% discount on publication fees until the end of the year. continue reading »

Improved Efficacy of Pembrolizumab When Combined With sEphB4-HSA in HPV-negative EphrinB2-positive HNSCC

News

July 22, 2024
PRESS RELEASE: On July 10, 2024, a new research paper was published in Oncotarget, entitled, “Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.” continue reading »